Inhibitor development in hemophiliacs: The roles of genetic versus environmental factors
(2006) In Seminars in Thrombosis and Hemostasis 32. p.41561-41561- Abstract
- Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to similar to 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. However, accumulating evidence clearly indicates that other genetic factors (e.g., major histocompatibility complex alleles and other immune-modulatory genes) and factors associated with treatment (e.g., type of FVIII concentrate, route of administration, and age of first exposure) may also influence the risk of inhibitor development. There is much interest in identifying such genetic and treatment-related factors to help minimize... (More)
- Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to similar to 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. However, accumulating evidence clearly indicates that other genetic factors (e.g., major histocompatibility complex alleles and other immune-modulatory genes) and factors associated with treatment (e.g., type of FVIII concentrate, route of administration, and age of first exposure) may also influence the risk of inhibitor development. There is much interest in identifying such genetic and treatment-related factors to help minimize the risk of inhibitor development and improve treatment outcomes. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/686410
- author
- Lee, Christine A. ; Lillicrap, David and Astermark, Jan LU
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- inhibitory antibodies to FVIII, inhibitor development, FVIII prophylaxis
- in
- Seminars in Thrombosis and Hemostasis
- volume
- 32
- pages
- 41561 - 41561
- publisher
- Georg Thieme Verlag
- external identifiers
-
- wos:000238852400003
- scopus:33745741765
- pmid:16804830
- ISSN
- 1098-9064
- DOI
- 10.1055/s-2006-946909
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- e7aaca0e-3758-4ec5-aea9-7780fed65f8c (old id 686410)
- date added to LUP
- 2016-04-01 16:43:58
- date last changed
- 2022-01-28 21:44:56
@article{e7aaca0e-3758-4ec5-aea9-7780fed65f8c, abstract = {{Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to similar to 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. However, accumulating evidence clearly indicates that other genetic factors (e.g., major histocompatibility complex alleles and other immune-modulatory genes) and factors associated with treatment (e.g., type of FVIII concentrate, route of administration, and age of first exposure) may also influence the risk of inhibitor development. There is much interest in identifying such genetic and treatment-related factors to help minimize the risk of inhibitor development and improve treatment outcomes.}}, author = {{Lee, Christine A. and Lillicrap, David and Astermark, Jan}}, issn = {{1098-9064}}, keywords = {{inhibitory antibodies to FVIII; inhibitor development; FVIII prophylaxis}}, language = {{eng}}, pages = {{41561--41561}}, publisher = {{Georg Thieme Verlag}}, series = {{Seminars in Thrombosis and Hemostasis}}, title = {{Inhibitor development in hemophiliacs: The roles of genetic versus environmental factors}}, url = {{http://dx.doi.org/10.1055/s-2006-946909}}, doi = {{10.1055/s-2006-946909}}, volume = {{32}}, year = {{2006}}, }